Cargando…

Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide

BACKGROUND: Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness. Despite advances in surgery and radio-chemotherapy, patients continue to have poor prognoses, with a survival rate of 14–15 months. Thus, new therapeutic strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Catanzaro, Daniela, Milani, Gloria, Bozza, Angela, Bernardi, Martina, Chieregato, Katia, Menarin, Martina, Merlo, Anna, Celli, Paola, Belli, Romina, Peroni, Daniele, Pozzato, Alessandro, Pozzato, Gianantonio, Raneri, Fabio Angelo, Volpin, Lorenzo, Ruggeri, Marco, Astori, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427848/
https://www.ncbi.nlm.nih.gov/pubmed/35715634
http://dx.doi.org/10.1038/s41416-022-01865-9
_version_ 1784778987219714048
author Catanzaro, Daniela
Milani, Gloria
Bozza, Angela
Bernardi, Martina
Chieregato, Katia
Menarin, Martina
Merlo, Anna
Celli, Paola
Belli, Romina
Peroni, Daniele
Pozzato, Alessandro
Pozzato, Gianantonio
Raneri, Fabio Angelo
Volpin, Lorenzo
Ruggeri, Marco
Astori, Giuseppe
author_facet Catanzaro, Daniela
Milani, Gloria
Bozza, Angela
Bernardi, Martina
Chieregato, Katia
Menarin, Martina
Merlo, Anna
Celli, Paola
Belli, Romina
Peroni, Daniele
Pozzato, Alessandro
Pozzato, Gianantonio
Raneri, Fabio Angelo
Volpin, Lorenzo
Ruggeri, Marco
Astori, Giuseppe
author_sort Catanzaro, Daniela
collection PubMed
description BACKGROUND: Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness. Despite advances in surgery and radio-chemotherapy, patients continue to have poor prognoses, with a survival rate of 14–15 months. Thus, new therapeutic strategies are needed. Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies. METHODS: Here, the anticancer activity of quantum molecular resonance (QMR) was investigated. For this purpose, three glioblastoma cell lines were tested, and the QMR effect was evaluated on cancer cell proliferation rate and aggressiveness. To clarify the QMR mechanism of action, the proteomic asset after stimulation was delineated. Mesenchymal stromal cells and astrocytes were used as healthy controls. RESULTS: QMR affected cancer cell proliferation, inducing a significant arrest of cell cycle progression and reducing cancer tumorigenicity. These parameters were not altered in healthy control cells. Proteomic analysis suggested that QMR acts not only on DNA replication but also on the machinery involved in the mitotic spindle assembly and chromosome segregation. Moreover, in a combined therapy assessment, QMR significantly enhanced temozolomide efficacy. CONCLUSIONS: QMR technology appears to be a promising tool for glioblastoma treatment.
format Online
Article
Text
id pubmed-9427848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94278482022-09-01 Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide Catanzaro, Daniela Milani, Gloria Bozza, Angela Bernardi, Martina Chieregato, Katia Menarin, Martina Merlo, Anna Celli, Paola Belli, Romina Peroni, Daniele Pozzato, Alessandro Pozzato, Gianantonio Raneri, Fabio Angelo Volpin, Lorenzo Ruggeri, Marco Astori, Giuseppe Br J Cancer Article BACKGROUND: Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness. Despite advances in surgery and radio-chemotherapy, patients continue to have poor prognoses, with a survival rate of 14–15 months. Thus, new therapeutic strategies are needed. Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies. METHODS: Here, the anticancer activity of quantum molecular resonance (QMR) was investigated. For this purpose, three glioblastoma cell lines were tested, and the QMR effect was evaluated on cancer cell proliferation rate and aggressiveness. To clarify the QMR mechanism of action, the proteomic asset after stimulation was delineated. Mesenchymal stromal cells and astrocytes were used as healthy controls. RESULTS: QMR affected cancer cell proliferation, inducing a significant arrest of cell cycle progression and reducing cancer tumorigenicity. These parameters were not altered in healthy control cells. Proteomic analysis suggested that QMR acts not only on DNA replication but also on the machinery involved in the mitotic spindle assembly and chromosome segregation. Moreover, in a combined therapy assessment, QMR significantly enhanced temozolomide efficacy. CONCLUSIONS: QMR technology appears to be a promising tool for glioblastoma treatment. Nature Publishing Group UK 2022-06-17 2022-09-01 /pmc/articles/PMC9427848/ /pubmed/35715634 http://dx.doi.org/10.1038/s41416-022-01865-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Catanzaro, Daniela
Milani, Gloria
Bozza, Angela
Bernardi, Martina
Chieregato, Katia
Menarin, Martina
Merlo, Anna
Celli, Paola
Belli, Romina
Peroni, Daniele
Pozzato, Alessandro
Pozzato, Gianantonio
Raneri, Fabio Angelo
Volpin, Lorenzo
Ruggeri, Marco
Astori, Giuseppe
Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
title Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
title_full Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
title_fullStr Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
title_full_unstemmed Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
title_short Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
title_sort selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427848/
https://www.ncbi.nlm.nih.gov/pubmed/35715634
http://dx.doi.org/10.1038/s41416-022-01865-9
work_keys_str_mv AT catanzarodaniela selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT milanigloria selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT bozzaangela selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT bernardimartina selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT chieregatokatia selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT menarinmartina selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT merloanna selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT cellipaola selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT belliromina selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT peronidaniele selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT pozzatoalessandro selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT pozzatogianantonio selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT ranerifabioangelo selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT volpinlorenzo selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT ruggerimarco selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide
AT astorigiuseppe selectivecellcyclearrestinglioblastomacelllinesbyquantummolecularresonancealoneorincombinationwithtemozolomide